VA Dual Sequential Therapy

NCT06929962 · tracked via the Priya Life Science China tracker

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Phase

Phase 4

Started

2025-04-24

Last updated

2026-09-01

Condition(s) studied

Helicobacter Pylori Infection

Investigational drug(s) / intervention(s)

Vonoprazan and Amoxicillin for the first 7 daysVonoprazan and Amoxicillin for the first 5 daysVonoprazan and Amoxicillin for the second 7 daysVonoprazan and Amoxicillin for the second 5 daysVonoprazan and Amoxicillin for 14 days

Vonoprazan and Amoxicillin for the first 7 days: 20mg Vonoprazan twice times daily and 1g Amoxicillin twice times daily for 7 days

Vonoprazan and Amoxicillin for the first 5 days: 20mg Vonoprazan twice times daily and 1g Amoxicillin twice times daily for 5 days

Vonoprazan and Amoxicillin for the second 7 days: 20mg Vonoprazan twice times daily and 1g Amoxicillin three times daily for 7 days

Vonoprazan and Amoxicillin for the second 5 days: 20mg Vonoprazan twice times daily and 1g Amoxicillin three times daily for 5 days

Vonoprazan and Amoxicillin for 14 days: 20mg Vonoprazan twice times daily and 1g Amoxicillin three times daily for 14 days

Study summary

Sequential therapy for Hp was first introduced by Zullo et al. in 2000 and consists of two phases: the first phase involves proton pump inhibitors with one antibiotic, and the second phase involves proton pump inhibitors with two antibiotics. Based on this, the investigators propose a modified sequential therapy, where the first phase uses vonoprazan combined with amoxicillin, and the second phase increases the amoxicillin dosage, forming a high-dose amoxicillin regimen. This new treatment strategy combines the staged nature of sequential therapy with the advantages of high-dose dual therapy, gradually increasing the drug dosage to help patients adapt and reduce side effects (such as nausea, vomiting, and diarrhea), thereby improving patient tolerance.

The primary aim of this study is to compare the vonoprazan combined with high-dose amoxicillin sequential therapy with standard dual therapy (14-day regimen) in terms of Hp eradication rates, efficacy, side effect incidence, and patient compliance, to evaluate its improved effectiveness. Additionally, the study will explore the impact of a shortened treatment duration on the modified dual sequential therapy's efficacy for Hp infection.

Eligible participants in this study will be randomly assigned to one of the following three treatment groups based on a pre-generated randomization sequence:

Control Group: Vonoprazan combined with high-dose amoxicillin dual therapy for 14 days (VADT-14): Vonoprazan 20mg twice daily + Amoxicillin 1g three times daily.

Experimental Group 1: Vonoprazan combined with amoxicillin dual sequential therapy for 14 days (VAST-14):

Days 1 to 7: Vonoprazan 20mg twice daily + Amoxicillin 1g twice daily. Days 8 to 14: Vonoprazan 20mg twice daily + Amoxicillin 1g three times daily.

Experimental Group 2: Vonoprazan combined with amoxicillin dual sequential therapy for 10 days (VAST-10):

Days 1 to 5: Vonoprazan 20mg twice daily + Amoxicillin 1g twice daily. Days 6 to 10: Vonoprazan 20mg twice daily + Amoxicillin 1g three times daily.

Eligibility

Sex

ALL

Min age

18 Years

Max age

70 Years

Healthy volunteers

Inclusion Criteria: 1. Aged 18-70 years, gender unrestricted. 2. Chronic gastritis patients with Helicobacter pylori positivity: (1) Helicobacter pylori positive is defined as a positive result on a carbon-13 or carbon-14 breath test within one month prior to enrollment; (2) Chronic gastritis is defined as a diagnosis based on gastroscopy within six months prior to enrollment. 3. No previous Helicobacter pylori eradication therapy. 4. Agree to participate in the trial and sign the informed consent form Exclusion Criteria: 1. Allergy to any of the drugs used in this clinical trial. 2. Previously received H. pylori eradication treatment. 3. Receiving Potassium-competitive acid blocker (P-CAB), proton pump inhibitor (PPI), H2 receptor antagonist, antibiotics, bismuth, probiotic preparations 4 weeks before initiating study treatment. 4. Use of non-steroidal anti-inflammatory drugs (NSAIDs), adrenal corticosteroids, or anticoagulants during the study period. 5. Pregnant or lactating women, or patients planning to conceive during the study period. 6. Patients with hepatic or renal dysfunction, or those with severe concomitant diseases that may affect the evaluation of this study, such as heart disease, lung disease, liver disease, kidney disease, metabolic disorders, mental illnesses, malignant tumors, etc.. 7. Gastroscopy findings indicating conditions other than gastritis, such as reflux esophagitis, which require continued use of potassium-competitive acid blockers (P-CABs), proton pump inhibitors (PPIs), H2 receptor antagonists, or bismuth after Helicobacter pylori eradication. 8. Patients with a history of gastric surgery. 9. Patients who are unable to accurately express their symptoms, such as those with psychiatric disorders or severe neurosis, and are unable to cooperate with the trial. 10. Patients who have participated in other drug studies within 3 months before using the investigational drug. 11. Other conditions deemed by the investigator as unsuitable for participation in this trial.

Primary outcome measure(s)

H. pylori eradication rate — 4-6 weeks after treatment completion
Rate of H. pylori successfully eradicated; The confirmation of H. pylori status was evaluated by Urea breath test.

Trial sites (1)

Facility	City	Region	Status
The First Affiliated Hospital with Nanjing Medical University	Nanjing	Jiangsu	Recruiting

More The First Affiliated Hospital with Nanjing Medical University trials in China

CPVI With Modified Linear Ablation Versus CPVI in Patients With Long-standing Persistent Atrial Fibrillation (SINUS) Recruiting

Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib Recruiting

A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11 Recruiting

Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer Starting soon

Ultrasound-Enhanced Delivery of Compound TXA Solution in Melasma Recruiting

Other trials for the same condition

Head-to-head Study of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID vs. Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID for H. Pylori Eradication Recruiting

Epidemiological Investigation of Helicobacter Pylori-infected Patients and the Effect of Eradication Treatment on Dyspepsia Symptoms Recruiting

The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients Recruiting

Fecal Molecular Susceptibility-guided Hp Rescue Therapy Starting soon

Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06929962 on ClinicalTrials.gov ↗ ← All trials in China